Advanced Glycation Endproducts and Bone Material Strength in T2D Treated With Pyridoxamine

Exclusion Criteria

• •Hormone replacement treatment (HTR) use (to avoid the influence of estrogen).
• •Fractures (excluding skull, facial bones, metacarpals, fingers, toes, and fractures associated with severe trauma) within 12 months.
• •A history of pathological fractures (eg, due to Paget's disease, myeloma, metastatic malignancy).
• •Type 1 diabetes
• •Disorders associated with altered skeletal structure or function (chronic liver disease' chronic renal disease stage 4 \[eGFR \< 30 mL/mim/1.73 m2\] or worse, malignancy, hypoparathyroidism or hyperparathyroidism,acromegaly, Cushing's syndrome, hypopituitarism, alcohol intake \> 3U/day).
• •Treatment with any of the following drugs in part year:current corticosteroid, anticonvulsant therapy(phenytoin, phenobarbital, primidone, carbamazepine), SGLT2 inhibitor if on it for \< 1 year), pharmacological doses of thyroid hormone (TSH\<normal), adrenal or anabolic steroids, Aromatase inhibitors, calcitonin, bisphosphonates, denosumab, estrogen, or selective estrogen receptor modulator, sodium fluoride, teriparatide, thiazolidinediones(TZDs).
• •Serum 25(OH)D levels \< 20 ng/ml. If 25(OH)D levels are \< 20 ng/ml, rescreening will be allowed following a vitamin D loading regimen of 50,000 IU/week for 4 weeks. If serum 25(OH) D levels are ≥ 20 ng/ml after supplementation, the subject will be allowed to enroll.
• •Current use of pyridoxamine (although not multivitamin or vitamin B6 users because pyridoxamine is not at pharmacologic levels in these supplements).
• •Allergy to pyridoxamine and vitamin B6.